ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,013.13
      -1.71%
      US Tech 100
      21,038.40
      -2.10%
      Dow Jones
      43,428.02
      -1.69%
      Brent Oil
      73.935
      0.00%
      Bitcoin
      96,294.98
      0.16%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Atea Pharmaceuticals Inc (AVIR) Quote

      Atea Pharmaceuticals Inc

      Atea Pharmaceuticals Inc (AVIR)

      NASDAQ
      3.09
      -0.05
      (-1.59%)
      Closed February 21 4:00PM
      Delayed by 15 minutes
      3.09
      0.00
      (0.00%)
      After Hours: 5:16PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      3.09
      Bid
      3.00
      Ask
      3.30
      Volume
      309,138
      3.05 Day's Range 3.19
      2.30 52 Week Range 4.60
      Market Cap
      260.991M
      Previous Close
      3.14
      Open
      3.19
      Last Trade
      6
      @
      3.0001
      Last Trade Time
      Financial Volume
      $ 965,729
      VWAP
      3.1239
      Average Volume (3m)
      433,909
      Shares Outstanding
      84,463,059
      Dividend Yield
      -
      PE Ratio
      -1.92
      Earnings Per Share (EPS)
      -1.61
      Revenue
      -
      Net Profit
      -135.96M

      About Atea Pharmaceuticals Inc

      Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treat... Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.ateapharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Atea Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVIR. The last closing price for Atea Pharmaceuticals was $3.14. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of $ 2.30 to $ 4.60.

      Atea Pharmaceuticals currently has 84,463,059 shares outstanding. The market capitalization of Atea Pharmaceuticals is $265.21 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.92.

      Ask ADVFN Intelligence (AI)

      AVIR Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 04 2025
      AVIR (-1.59%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 04 2025
      AVIR (-1.59%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 04 2025
      AVIR (-1.59%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 04 2025
      AVIR (-1.59%)

      Form EFFECT - Notice of Effectiveness
      Edgar (US Regulatory)
      November 20 2024
      AVIR (-1.59%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.05-1.59235668793.143.253.042171863.11760993CS
      4-0.01-0.3225806451613.13.252.93275163.06468617CS
      12-0.28-8.308605341253.373.5992.754339093.15837778CS
      26-0.71-18.68421052633.84.1452.32970243.31376633CS
      52-1.24-28.63741339494.334.62.32873453.54955392CS
      156-2.77-47.26962457345.869.792.34650884.7507563CS
      2602.2675275.6838905780.822594.17370.822582439214.80528647CS

      AVIR - Frequently Asked Questions (FAQ)

      What is the current Atea Pharmaceuticals share price?
      The current share price of Atea Pharmaceuticals is $ 3.09
      How many Atea Pharmaceuticals shares are in issue?
      Atea Pharmaceuticals has 84,463,059 shares in issue
      What is the market cap of Atea Pharmaceuticals?
      The market capitalisation of Atea Pharmaceuticals is USD 265.21M
      What is the 1 year trading range for Atea Pharmaceuticals share price?
      Atea Pharmaceuticals has traded in the range of $ 2.30 to $ 4.60 during the past year
      What is the PE ratio of Atea Pharmaceuticals?
      The price to earnings ratio of Atea Pharmaceuticals is -1.92
      What is the reporting currency for Atea Pharmaceuticals?
      Atea Pharmaceuticals reports financial results in USD
      What is the latest annual profit for Atea Pharmaceuticals?
      The latest annual profit of Atea Pharmaceuticals is USD -135.96M
      What is the registered address of Atea Pharmaceuticals?
      The registered address for Atea Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Atea Pharmaceuticals website address?
      The website address for Atea Pharmaceuticals is www.ateapharma.com
      Which industry sector does Atea Pharmaceuticals operate in?
      Atea Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      BOXLBoxlight Corporation
      $ 3.1099
      (51.70%)
      		1.84M
      GDEVGDEV Inc
      $ 20.90
      (46.56%)
      		264.44k
      IVVDInvivyd Inc
      $ 1.7501
      (44.64%)
      		37.75M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      DOYUDouYu International Holdings Ltd
      $ 7.19
      (-55.31%)
      		1.28M
      MNDRMobile health Network Solutions
      $ 0.5048
      (-46.29%)
      		18.61M
      BLUEbluebird bio Inc
      $ 4.09
      (-41.90%)
      		5.44M
      GCLGCL Global Holdings Ltd
      $ 3.83
      (-31.48%)
      		635.26k
      AXTIAXT Inc
      $ 1.57
      (-31.44%)
      		6.66M
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      ADTXAditxt Inc
      $ 0.0922
      (-22.39%)
      		278.25M
      NVDANVIDIA Corporation
      $ 134.43
      (-4.05%)
      		228.14M
      HOLOMicroCloud Hologram Inc
      $ 1.565
      (31.51%)
      		190.81M

      AVIR Discussion

      View Posts
      DewDiligence DewDiligence 5 months ago
      AVIR phase-3 COVID trial fails—stock rises:

      https://www.globenewswire.com/news-release/2024/09/13/2945844/0/en/Atea-Pharmaceuticals-Provides-Update-on-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Bemnifosbuvir-for-Treatment-of-COVID-19.html Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)…today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. This trial was a longshot insofar as Bemnifosbuvir is a repurposed HCV drug rather than something designed specifically for SARS-CoV-2. Moreover, the phase-2 trial for Bemnifosbuvir in COVID was unsuccessful, but AVIR plowed ahead anyhow.

      I presume the share price is up slightly today because investors know that AVIR won’t waste more money pursuing COVID. AVIR had about $475M of net current assets as of 6/30/24.

      AVIR’s CEO, Jean-Pierre Sommadossi, is continuing to pursue a treatment regimen for HCV, which is a rather extreme case of Zebra’s Law (#msg-172559198).
      👍️0
      Monksdream Monksdream 6 months ago
      AVIR under $4
      👍️0
      DewDiligence DewDiligence 7 months ago
      AVIR reports 2Q24 results—6/30/24 cash=$502.2M—down_from_$542M_at_3/31/24:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500091.html

      CC slides:
      https://ir.ateapharma.com/static-files/96ee237a-23d9-4515-8401-69794a5327e0
      👍️0
      DewDiligence DewDiligence 9 months ago
      AVIR 1Q24 results:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html

      3/31/24 cash = $542M, down from $578M at 12/31/23.

      Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).
      👍️0
      Monksdream Monksdream 10 months ago
      AVIR under $5
      👍️0
      DewDiligence DewDiligence 11 months ago
      AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

      https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…
      👍️0
      DewDiligence DewDiligence 12 months ago
      AVIR phase-3 COVID update:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

      The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

      AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR rejects Tang buyout offer, as expected:

      https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

      The offer was for less than AVIR’s cash value.
      👍️0
      DewDiligence DewDiligence 2 years ago
      It's not a serious offering for the reason mentioned in #msg-171974875.
      👍️0
      mwn mwn 2 years ago
      Why is the sp going so far below the offering?
      👍️0
      DewDiligence DewDiligence 2 years ago
      Yes.
      👍️0
      Paullee Paullee 2 years ago
      Did you not notice that a CVR of 80% is included in the package?
      👍️0
      DewDiligence DewDiligence 2 years ago
      In other words, AVIR could do better than $5.75/sh by simply liquidating.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

      https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

      Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.
      👍️0
      DewDiligence DewDiligence 2 years ago
      Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

      https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

      Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .
      👍️0
      Awl416 Awl416 2 years ago
      Volume
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 1Q23 CC transcript:

      https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 1Q23 results:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

      3/31/23 cash = $621M.
      👍️0
      V63 V63 2 years ago
      So AVIR beat its earnings, and now it might bump up a little tomorrow.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR reports final data from phase-2 COVID trial:

      https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 4Q22 CC transcript:

      https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 4Q22 results—12/31/22 cash=$647M:

      https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

      AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR JPM webcast slides:

      https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 2023 newsflow:

      https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 3Q22 results—9/30/22 cash=$665M:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

      A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

      The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).
      👍️0
      DewDiligence DewDiligence 3 years ago
      AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html
      👍️0
      DewDiligence DewDiligence 3 years ago
      AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

      1Q22 PR:
      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

      1Q22 CC slides:
      https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562
      👍️0
      DewDiligence DewDiligence 3 years ago
      LOL re AVIR’s attempt to be relevant:

      https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html
      👍️0
      Jake L Jake L 3 years ago
      AVIR - Friday Rundown, Monday Expectations

      👍️0
      Wallst_junkie Wallst_junkie 3 years ago
      Watching for a uptrend
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Wow! That's why you don't hold these Pharma overnight.

      AVIR
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR
      👍️0
      DewDiligence DewDiligence 3 years ago
      Why AVIR's AT-527 program is no-go: #msg-166425975.
      👍️0
      XWAVXALMIMAN XWAVXALMIMAN 3 years ago
      David v Goliath

      Interesting article - check out RDHL

      https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html
      👍️0
      Chess Master Chess Master 3 years ago
      What a drop
      👍️0
      ecommceo ecommceo 3 years ago
      Way over sold here.
      👍️0
      Planopenny Planopenny 3 years ago
      Out at $16, easy $$$
      👍️0
      Docstemcell2020 Docstemcell2020 3 years ago
      Let's go Brandon! FJB :)
      👍️0
      DewDiligence DewDiligence 3 years ago
      AVIR CC slides (largely BS, IMO):

      https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6
      👍️0
      Planopenny Planopenny 3 years ago
      In at $10
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      Thanks DD
      👍️0
      DewDiligence DewDiligence 3 years ago
      The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

      https://clinicaltrials.gov/ct2/show/NCT04575597
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

      But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.
      👍️0
      Whalatane Whalatane 3 years ago
      AVIR presentation tomorrow Oct 5th

      https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

      Kiwi
      👍️0
      crudeoil24 crudeoil24 3 years ago
      You bet! > AVIR up 45% @ 50.05
      👍️0
      Whalatane Whalatane 3 years ago
      Thx for the updates

      Kiwi
      👍️0
      crudeoil24 crudeoil24 3 years ago
      AVIR up 45% @ 50.05 > premarket.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      AVIR > 53M share trading float.
      👍️0

      Your Recent History

      NASDAQ
      AVIR
      Atea Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads